论文部分内容阅读
组织型纤溶酶原激活物（ｔＰＡ）和尿激酶型纤溶酶原激活物（μＰＡ）可使纤溶酶原转变为纤溶酶，参与纤溶、炎症、细胞迁移、排卵、肿瘤浸润和转移等许多生理和病理过程。Ⅰ型纤溶酶原激活物抑制剂（ＰＡＩ－１）是这两者主要的快速作用的抑制剂，它能抑制ＰＡ介导的纤溶活性
Tissue plasminogen activator (tPA) and urokinase-type plasminogen activator (μPA) convert plasminogen to plasmin and are involved in fibrinolysis, inflammation, cell migration, ovulation, tumor invasion and Transfer and many other physiological and pathological processes. Type I plasminogen activator inhibitor (PAI-I) is a major, rapid-acting inhibitor of both, which inhibits PA-mediated fibrinolytic activity